Integris Medtech IPO

Upcoming Mainboard Pharmaceuticals
Next: Bidding opens in 5 days (Nov 27)
Listing On BSE & NSE

Market Sentiment

GMP, subscription and the analysis score appear here once grey-market quotes and bidding begin. This section updates automatically.

IPO Details

Face Value₹1 Per Equity Share
Fresh Issue₹600.00 crore
Issue TypeBook-Building IPO
Lead Managers Axis Capital Ltd , Citigroup Global Markets India Pvt Ltd
Registrar KFin Technologies Limited
PromotersEvercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh, Punita Sharma
Listing atBSE & NSE

IPO Reservation

Reservation details not available yet
This section updates automatically once data is available.

Financial Analysis

Financial Data

EPS (Pre)
₹5.82
ROE
5.35%
ROCE
14.51%
RoNW
1.84%
EBITDA Margin
16.26%
NAV/Share
₹316.09
Revenue Growth
23.85%
Profit Margin
3.61%

Financial Performance

31 Mar 2025 vs 31 Mar 2024 Revenue +23.8% Total Assets +21.8%
Metric 31 Mar 2023 31 Mar 2024 31 Mar 2025 30 Jun 2025
Revenue 1,369.66 1,582.26 1,959.58 508.93
Profit (PAT) -40.54 -4.88 70.68 267.57
Total Assets 2,553.87 2,989.20 3,641.34 4,019.62
Values in Crores (₹)

Peer Comparison

Company EPS P/E RoNW % NAV Income
Integris Medtech This IPO 5.82 - 1.84 316.09 -
Laxmi Dental Limited 6.07 53.95 16.09 37.71 239.11 Cr
Poly Medicure Limited 34.13 56.02 12.26 278.46 1,669.83 Cr
Peer median P/E 55.0x across 2 listed peers

Strengths & Risks

Strengths
  • Revenue grew 24% in the latest reported year.
Risks & Concerns
  • Modest return on equity — 5%.

From this issue's live data. Not investment advice — read the RHP.

Company Information

Integris Medtech at a glance

From the company's description: “Founded in 2008, Integris Medtech is one of the leading global medical products and laboratory solutions providers in India.”

Integris Medtech is raising an undisclosed amount through an IPO on the BSE and NSE mainboard in the Pharmaceuticals sector. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applic… (₹510 crore), The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Su… (₹416 crore) and The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhe… (₹93.87 crore).

Written from the issue's offer-document figures shown on this page. Not investment advice.

Company Contact Information

Integris Medtech Ltd., 1 st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, North Delhi, New Delhi, 110060

Objects of the Issue

Purpose Amount (Cr)
Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: 509.85
The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. 93.87
The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. 415.98
General Corporate Purposes -

Resources & Documents

Integris Medtech IPO - Quick Take

Integris Medtech is preparing a mainboard offering in the pharmaceuticals sector. The Mainboard issue is scheduled to open for subscription on November 27, 2026 — 5 days from now.

The company operates in the pharmaceuticals space.

The issue is promoted by Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh, Punita Sharma with Axis Capital Ltd, Citigroup Global Markets India Pvt Ltd, ICICI Securities Ltd, Iifl Securities Ltd acting as lead manager. Net proceeds will primarily be used towards repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties,… (Rs 510 crore) and the wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd… (Rs 94 crore).

On fundamentals, the company is posting revenue growth of 23.9%, a profit margin of 3.6%, return on equity of 5.4% in its most recent reported period. Listed peers in this segment include Laxmi Dental Limited (P/E 53.95x) and Poly Medicure Limited (P/E 56.02x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.

All figures below — GMP history, subscription tiers, financials and peers — are aggregated from public disclosures. Always apply through your own broker after reading the RHP.

Integris Medtech IPO: Lead Manager & Registrar Track Record

How the firms running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Integris Medtech itself, so they describe what came before it.

Mainboard IPOs, last 12 months
  • 71% of 114 listings opened above the issue price; median listing-day move +6.8%.
  • Average listing-day move across all 114 Mainboard listings we track: +13.6%.
Lead manager and registrar record on other IPOs we track
Firm Other IPOs Listed at / above issue Avg move Median
Axis Capital Ltd Lead manager 23 23 MB · 0 SME 89% 17 of 19 +14.7% +6.7%
Citigroup Global Markets India Pvt Ltd Lead manager 6 6 MB · 0 SME 67% 2 of 3 +3.3% +0.8%
ICICI Securities Ltd Lead manager 22 22 MB · 0 SME 70% 14 of 20 +16.6% +5.6%
Iifl Securities Ltd Lead manager 1 1 MB · 0 SME 100% 1 of 1 +64.7% +64.7%
KFin Technologies Limited Registrar 101 56 MB · 45 SME 81% 79 of 97 Check allotment →
Recent listings managed by Axis Capital Ltd (5)

Best: Moneyview +63.6% · Weakest: Clean Max Enviro −8.8%

IPOListedListing-day move
EAAA India Alternatives 02 Nov 2026 +0.6%
Jio Platforms 28 Oct 2026 +21.4%
Bonfiglioli Transmissions 23 Oct 2026 +0%
Moneyview 01 Oct 2026 +63.6%
NSE 24 Sep 2026 +0.8%
Recent listings managed by Citigroup Global Markets India Pvt Ltd (3)

Best: Jio Platforms +21.4% · Weakest: Amagi Media Labs −12.2%

IPOListedListing-day move
Jio Platforms 28 Oct 2026 +21.4%
NSE 24 Sep 2026 +0.8%
Amagi Media Labs 21 Jan 2026 −12.2%
Recent listings managed by ICICI Securities Ltd (5)

Best: Tempsens Instruments +111.3% · Weakest: Turtlemint Fintech −11.3%

IPOListedListing-day move
Jio Platforms 28 Oct 2026 +21.4%
Bonfiglioli Transmissions 23 Oct 2026 +0%
Runwal Enterprises 05 Oct 2026 +0.3%
NSE 24 Sep 2026 +0.8%
Hero Motors 23 Sep 2026 −2.3%
Recent listings managed by Iifl Securities Ltd (1)
IPOListedListing-day move
Orient Cables 05 Oct 2026 +64.7%
What a lead manager does

A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.

What a registrar does

Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.

Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.

Frequently Asked Questions

Integris Medtech IPO consists of fresh issue of Rs 600 crore.

Integris Medtech IPO opens for subscription on November 27, 2026 and closes on December 01, 2026.

The expected allotment date for Integris Medtech IPO is December 02, 2026. Refunds for unsuccessful applicants are expected on December 03, 2026. Shares are scheduled to be credited to demat accounts on December 03, 2026.

Integris Medtech IPO is scheduled to list on December 04, 2026 on both BSE and NSE.

The registrar for Integris Medtech IPO is KFin Technologies Limited. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Integris Medtech IPO are Axis Capital Ltd, Citigroup Global Markets India Pvt Ltd, ICICI Securities Ltd, Iifl Securities Ltd.

The promoter(s) of Integris Medtech are Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh, Punita Sharma.

You can apply for Integris Medtech IPO online before 01 Dec 2026 through any UPI-enabled broker app (Zerodha, Groww, Upstox, Angel One, ICICI Direct, HDFC Securities, or any SEBI-registered broker), or via your bank's ASBA-enabled net banking. Steps: (1) Open your broker app or your bank's ASBA portal. (2) Search for Integris Medtech in the IPO section — the issue must be in the Open window to apply. (3) Enter your bid: select the number of lots (minimum 1 lot) and bid at the cut-off price, so your bid stays valid wherever in the band the final price is set. (4) Approve the UPI mandate that arrives on your bidding bank account — this blocks the application amount until allotment, and the funds stay in your account until shares are allotted. Allotment is finalized on T+1, the working day after the close date, and the shares list on T+3. See our How to Apply for an IPO guide for step-by-step screenshots, and the ASBA vs UPI Mandate explainer for how the payment block works.

The full breakdown is on this page, and our How We Score IPOs guide explains the method. This is a summary of public data, not investment advice or a recommendation to apply. Read the RHP and consult a SEBI-registered investment adviser before investing.

Integris Medtech IPO GMP — What It Means

No active grey market premium has been recorded for Integris Medtech IPO yet. GMP is an unofficial, dealer-quoted indicator of expected listing-day demand — not a guaranteed listing price — and it can change quickly once bidding opens.

See the full Integris Medtech GMP history and trend, or learn how grey market premium works and how reliable it is.

Related IPO

Same sector or same stage as Integris Medtech
Side by side: GMP, subscription, valuation, financials and listing performance.
0 Comments

No comments yet. Be the first to share your opinion!

GMPUpdate